-+ 0.00%
-+ 0.00%
-+ 0.00%
ProBio Signs Exclusive Global Licensing Deal With AbTis for Cancer Drug Development
Share
Listen to the news
ProBio Signs Exclusive Global Licensing Deal With AbTis for Cancer Drug Development
  • ProBio signed an exclusive global licensing agreement with AbTis for a discovery-stage oncology antibody asset.
  • AbTis gains exclusive worldwide development and commercialization rights, with plans to develop a next-generation antibody-drug conjugate using its AbClick platform.
  • The agreement includes an upfront payment to ProBio, potential development and commercial milestone payments, and royalties on future sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CL81758) on November 10, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending